The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.
The adoption of automated molecular platforms for blood screening has emerged as a key strategy among leading market players, significantly accelerating market growth. Blood screening tests are specifically developed to ensure the safety of donated blood units and to identify markers of transfusion-transmissible infections (TTIs). The rising number of blood donations and an expanding donor base, coupled with growing awareness about the safety of donated blood, are driving the market forward. Additionally, the increasing prevalence of infectious diseases, along with various government initiatives aimed at improving blood safety standards, are major factors propelling the growth of the blood screening market.
Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/blood-screening-market-102552
Blood Screening Market Trend:
The Blood Screening Market is witnessing steady evolution, largely driven by the rising demand for early disease detection and prevention. One key trend is the shift toward nucleic acid testing (NAT), which offers faster and more accurate detection of infections like HIV, Hepatitis B, and Hepatitis C. Automation and integration of advanced technologies in blood screening systems are also improving testing speed and reliability. Furthermore, there's a growing focus on expanding screening in low- and middle-income countries, thanks to government and NGO initiatives promoting safe blood transfusion practices.
Blood Screening Market Growth:
The Blood Screening Market is growing rapidly as healthcare systems place greater emphasis on safety, especially in blood banks and hospitals. With the increase in surgical procedures, trauma cases, and chronic diseases, the need for clean, infection-free blood has never been higher. Additionally, the rise in voluntary blood donations globally is pushing the need for robust screening solutions. Combined with supportive healthcare regulations and growing awareness about transfusion-transmitted infections (TTIs), the market is set for consistent expansion in the coming years.
Blood Screening Market Segmentation:
The Blood Screening Market can be segmented based on technology, product type, end-user, and application.
By technology, the Blood Screening Market is divided into nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid testing, and others. NAT is gaining significant traction due to its accuracy and faster results, while ELISA remains widely used in many laboratories for its affordability and proven reliability.
In terms of product type, the Blood Screening Market includes reagents & kits, instruments, and software & services. Reagents and kits account for the largest share, as they are essential for conducting each screening procedure. However, advanced instruments and software for automating the testing process are also seeing increased demand, especially in large hospitals and diagnostic labs.
By end-user, the Blood Screening Market is segmented into blood banks, hospitals, diagnostic laboratories, and others. Blood banks are the largest users, given their role in managing blood donations and storage. Hospitals and diagnostic labs also contribute significantly, particularly in regions where transfusion-related diseases are a major concern.
When segmented by application, the Blood Screening Market includes hepatitis, HIV, syphilis, and others. Hepatitis and HIV screening dominate due to the high prevalence and risk associated with these infections. As awareness and preventive healthcare efforts grow, applications in other areas like malaria and Zika virus are also being incorporated into routine screening practices.
List Of Key Companies Profiled:
Bio-Rad Laboratories, Inc.
Grifols, S.A.
Hoffmann-La Roche
Ortho Clinical Diagnostics
BD
DiaSorin S.p.A.
Thermo Fisher Scientific Inc.
Abbott
QUOTIENT
Other Players
Blood Screening Market Restraining Factors:
Despite its growth potential, the Blood Screening Market faces a few challenges. The high cost of advanced screening tests and equipment can be a significant barrier, especially in developing regions. Smaller labs and healthcare facilities often struggle with budget constraints, limiting their ability to adopt newer technologies. Additionally, a shortage of trained personnel and inconsistent regulatory frameworks across countries may slow the pace of global market adoption.
Blood Screening Market Regional Analysis:
Regionally, North America holds the largest share of the Blood Screening Market, driven by strong healthcare infrastructure, frequent blood donations, and advanced screening technologies. Europe follows closely, with high standards for blood safety and a growing elderly population needing transfusions. The Asia-Pacific region is seeing rapid growth due to rising healthcare awareness, government-led health programs, and increasing investment in healthcare infrastructure. Meanwhile, Latin America and the Middle East & Africa are gradually adopting blood screening solutions, supported by international aid and efforts to improve public health and blood safety standards.
Key Industry Developments:
In June 2021, Grail, a U.S.-based biotechnology and pharmaceutical company, announced the launch of its Galleri blood test — an innovative multi-cancer screening diagnostic designed to detect the presence of multiple cancer types. With this groundbreaking test, the company aims to screen approximately 50 million individuals following its launch and is targeting full FDA approval by 2023.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free)
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com